Anthranilimide-based Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes: 1. Identification of 1-amino-1-cycloalkyl Carboxylic Acid Headgroups

Optimization of the amino acid residue within a series of anthranilimide-based glycogen phosphorylase inhibitors is described. These studies culminated in the identification of anthranilimides 16 and 22 which displayed potent in vitro inhibition of GPa in addition to reduced inhibition of CYP2C9 and excellent pharmacokinetic properties.